HDM3020 / Huadong Medicine - LARVOL DELTA

A Novel Anti-TNFα/OX40L Bispecific Antibody Breaks the Innate-Adaptive Immunity Loop for Potential Remission in Rheumatoid Arthritis therapies (ACR Convergence 2026) - "HDM3020 represents a differentiated next-generation dual-targeting auto-immune therapy that disrupts the innate-adaptive immunity loop through synergistic TNFα and OX40L blockade. Its moderate OX40L affinity and potent TNFα inhibition achieve an optimized efficacy-safety profile differentiated from current monotherapies and clinical-stage bispecifics. Supported by favorable cynomolgus monkey PK profile, a Q4W subcutaneous and stable liquid formulation is developed."

Bispecific • Clinical • Immunology • Infectious Disease • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IFNG • IL2 • TNFSF4